John Harley
President, Owl Biomedical, Inc.
Professional Overview
John Harley is an accomplished executive with over 20 years of experience in the biotech and microfluidics industries. As the President of Owl Biomedical, Inc., he leverages his deep technical expertise and strategic leadership to drive innovation and growth within the organization.
Experience Summary
Current Role
As the President of Owl Biomedical, Inc. since November 2019, John is responsible for setting the company's strategic vision, leading cross-functional teams, and spearheading the development of cutting-edge biomedical technologies. Under his guidance, Owl Biomedical has expanded its product portfolio, secured key partnerships, and solidified its position as a leader in the field.
Career Progression
Prior to joining Owl Biomedical, John held various leadership roles at Micralyne, where he served as the President and CEO from 2019 to 2019, and as the Vice President of Strategic Marketing and Business Development from 2016 to 2019. Before that, he held progressively senior positions at Innovative Micro Technology, including Vice President of Product and Process Engineering, Director of Product Engineering, and several program management roles.
John's early career was marked by his work as a Consultant at JCHarley Inc., a Biotech and Microfluidics Market Specialist at Coventor, Inc. (a Lam Research Company), and an Engineer at Fluent, Inc. Throughout his career, he has demonstrated a strong track record of driving innovation, fostering collaboration, and delivering measurable results.
Academic Background
John holds a Bachelor's degree in Mechanical Engineering from the University of California, Santa Barbara, where he graduated with distinction.
Areas of Expertise
- Biomedical technology development
- Microfluidics and lab-on-a-chip systems
- Strategic marketing and business development
- Cross-functional team leadership
- Technology commercialization and product launch
Professional Impact
Under John's leadership, Owl Biomedical has introduced several groundbreaking biomedical products, including a novel microfluidic-based diagnostic platform that has significantly improved the accuracy and efficiency of disease detection. Additionally, John has spearheaded the company's expansion into new markets, forged strategic partnerships with industry leaders, and secured funding to support ongoing research and development initiatives.
Conclusion
With his extensive industry experience, exceptional technical expertise, and visionary leadership, John Harley is poised to continue driving Owl Biomedical's growth and innovation. His commitment to advancing the field of biomedical technology and his ability to translate scientific breakthroughs into successful commercial products make him a valuable asset to the organization and the industry as a whole.
